by Terasaki Institute for Biomedical Innovation Researchers have developed a method for injectable, targeted delivery of immunotherapeutic treatments. The shear-thinning biomaterial is loaded with the ICI, which can then be delivered and released at the tumor site. The ICIs bind to T cells, preventing binding and T cell suppression by the tumor cells. This frees...
